Fulcrum Biopharma Allocates Majority Stake to Slate Investors Amid Dividend Debate

Fulcrum Therapeutics is distributing 95% of its combined company equity to Slate Capital and PIPE investors following a major transaction, prompting questions about whether the proposed $270 million dividend adequately compensates shareholders.